Table 2.
Population baseline characteristics and distribution between responders and nonresponders.
| Variables | All patients (n = 178, 100%) |
Responders (n = 106, 59.5%) |
Nonresponders(n = 72, 40.5%) | p value |
|---|---|---|---|---|
| Age | 70 ± 10 | 70.4 ± 10 | 70 ± 9 | 0.729 |
| Males | 120 (67.4%) | 62 (58.5)% | 58 (80.6%) | 0.002 |
| Females | 58 (32.6%) | 44 (41.5%) | 14 (19.4%) | |
| NYHA class II | 32 (18.0%) | 23 (21.7%) | 9 (13.5%) | 0.117 |
| III | 146 (82.0%) | 83 (78.3%) | 63 (87.5%) | |
| Ischemic etiology | 64 (35.9%) | 36 (34.0%) | 28 (38.9%) | 0.457 |
| QRS (ms) | 161 ± 18 | 163 ± 18 | 158 ± 18 | 0.115 |
| AF | 20 (11.2%) | 6 (5.7%) | 14 (19.4%) | 0.004 |
| Hypertension | 85 (47.7%) | 67 (63.2%) | 45 (62.5%) | 0.996 |
| DM | 46 (25.8%) | 21 (19.8%) | 25 (34.7%) | 0.022 |
| Dyslipidemia | 72 (40.4%) | 41 (38.7%) | 31 (43.1%) | 0.776 |
| ACE-is/ARBs | 160 (89.9%) | 97 (91.5%) | 62 (86.1%) | 0.367 |
| Beta-blockers | 142 (79.8%) | 89 (84.0%) | 53 (73.6%) | 0.127 |
| Statins | 70 (39.3%) | 39 (36.8%) | 31 (43.1%) | 0.360 |
| MRAs | 81 (45.5%) | 50 (47.2%) | 30 (41.7%) | 0.519 |
| Diuretics | 148 (83.1%) | 86 (81.1%) | 61 (84.7%) | 0.354 |
| LVEF (%) | 27.5 ± 5.6 | 26.8 ± 5.5 | 28.6 ± 5.5 | 0.037 |
| LVEDV (mL) ∗ | 192 (152–228) | 193 (165–229) | 177 (132–227) | 0.156 |
| LVESV (mL) ∗ | 137 (110–170) | 140 (116–175) | 135 (94–165) | 0.244 |
| LVEDD (mm) | 69.2 ± 10.2 | 68.3 ± 9.4 | 70.7 ± 11.3 | 0.238 |
| LVESD (mm) | 57.8 ± 11.3 | 57.4 ± 10.8 | 58.5 ± 12.3 | 0.638 |
| Selvester score | 7 (4–10) | 5 (3–8) | 8 (6–12) | <0.001 |
| Selvester score ≥ 7 | 42 (39.6) | 47 (65.3%) | 0.001 | |
| Fragmented QRS | 74 (41.6%) | 42 (39.6%) | 32 (44.4%) | 0.457 |
Continuous variables are expressed as mean ± SD, and compared by the independent samples Student's t-test, or as median and 25°/75° percentiles, and compared by the Mann–Whitney U test, as appropriate ( ∗); categorical variables as number of patients (%) and compared by the χ2 test. AF, atrial fibrillation; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; DM, diabetes mellitus; ACE-I, angiotensin converting enzyme-inhibitors; ARBs, angiotensin receptor blockers; MRAs, mineralocorticoid receptor antagonists; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; and LVESV, left ventricular end-systolic volume.